Anticoagulants Market Size, Share, Trends & Industry Analysis, By Disease Indication (Pulmonary Embolism (PE), Deep Vein Thrombosis (DVT), Atrial Fibrillation, Heart Attacks, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Regional Forecast, 2025-2032

The global anticoagulants market size was valued at USD 37.69 billion in 2024, The market is projected to grow from USD 41.41 billion in 2025 to USD 80.29 billion by 2032, exhibiting a CAGR of 9.9% during the forecast period. North America dominated the global market with a share of 50.14% in 2024.

In this era, a number of critical and serious diseases have shown increasing prevalence across the global landscape. One of these critical diseases is cardiovascular disease, a disorder that has witnessed high prevalence worldwide, especially driven by modern lifestyle changes. The cardiovascular diseases include disorders of the heart and blood vessels, especially, and include life-threatening conditions such as coronary heart disease, hypertension, and hyperlipidemia. Cardiovascular diseases can result in conditions such as myocardial infarction. i.e., heart attacks and strokes.

According to the World Health Organization (WHO), four out of five cardiovascular disease (CVD) deaths are attributable to heart attacks and strokes. Generally, cardiovascular disorders are treated by a suite of cardiovascular drugs, one of whose critical components is the anticoagulants. Without the presence of effective anticoagulants, there is a greater possibility of the formation of blood clots and lead to heart attacks and other serious conditions.

In the current global blood thinners market scenario, there are a number of factors providing major impetus to the growth of these drugs. There is an increased awareness with respect to cardiovascular health and the possible repercussions or negative impact to its neglect. Blood-thinning medications often play a crucial role in human cardiovascular health protection by controlling and preventing the creation of blood clots.

Some of the other factors contributing to the growth of the global blood thinners market is the launch of new types of therapeutics known as novel oral anticoagulants (NOACs). These include a number of product offerings such as apixaban and rivaroxaban.

Global Anticoagulants Market Overview

Anticoagulants Market Size:

• 2024 Value: USD 37.69 Billion
• 2025 Value: USD 41.41 Billion
• 2032 Forecast Value: USD 80.29 Billion, with a CAGR of 9.9% from 2025–2032

Anticoagulants Market Share:

• North America led the anticoagulants market with a 50.14% share in 2024, driven by high cardiovascular disease prevalence and strong new product launches.
• By distribution channel, the hospital pharmacies segment is expected to hold a 46.1% share in 2025.

Key Country Highlights:

• The anticoagulants market in Japan is expected to reach USD 3.21 billion by 2025.
• China is forecast to witness a strong CAGR of 13.40%, while Europe is anticipated to grow at a CAGR of 7.6% during the forecast period.
• By disease indication, the pulmonary embolism segment is projected to generate USD 31.53 billion in revenue by 2025.

MARKET DRIVERS

Download Free sample to learn more about this report.

“Increased Awareness and Innovation of Blood Thinners is likely to propel the Global Market”

One of the crucial drivers for global market growth is the increased awareness regarding cardiovascular health and the corresponding increase in new therapeutic launches. Cardiovascular treatment through therapeutics includes a multi-faceted approach which may lead to the use of several types of medications, but blood thinning medications is a critical component of that treatment regime. A number of key market leaders have introduced several anticoagulants, addressing the critical treatment needs with respect to prevention of blood clots. For instance, the introduction of an anticoagulant called Eliquis (apixaban) by Bristol-Myers Squibb Company and Pfizer Inc. The product has high sales and has demonstrated superior risk reductions as compared to other drugs in the global scenario.

“Increasing Need for Advanced and Effective Drugs to Drive the Global Market”

Other critical driving factors are the high prevalence of cardiovascular diseases (CVD) globally and the increasing demand for more effective blood thinners. Anticoagulants have undergone major R&D innovations since the time they were initially introduced to the general public. A number of novel therapeutics such as novel oral anticoagulants (NOACs) have since been launched in the global market and have been highly successful. The global market scenario is now composed of two major anticoagulants: Eliquis and Xarelto. A greater presence of generics and other anticipated launches of anticoagulant generics may negatively impact the market. But, the nature of cardiovascular diseases (CVD) has rendered it almost incurable and the rising prevalence is further worsening the treatment outlook for patients. This has several unmet treatment needs in the market and is anticipated to be one of the other key driving factors in the global market.

Anticoagulants Market SEGMENTATION Analysis 

By Disease Indication Outlook

“Pulmonary Embolism (PE) Segment is Likely to Generate the Highest Growth Rate”

The global blood-thinning medication market can be segmented by disease indication into pulmonary embolism (PE), deep vein thrombosis (DVT), atrial fibrillation (AF), heart attacks, and others.

The pulmonary embolism (PE) segment is estimated to hold a dominant anticoagulants market share, because the most commercially successful anticoagulant, Eliquis, is indicated for this condition. Pulmonary embolism is a blood clot that occurs in the pulmonary arteries of the lungs and blocks the flow of blood. This condition is potentially life-threatening and may subsequently lead to another serious condition known as deep vein thrombosis (DVT). The increasing prevalence of pulmonary embolism due to other contributing factors, such as obesity, heart disease, and cancer, is further anticipated to drive the market growth. By Disease Indication, the pulmonary embolism segment is projected to generate USD 31.53 billion in revenue by 2025.

To know how our report can help streamline your business, Speak to Analyst

Some of the other factors that have contributed to the high growth of the deep vein thrombosis (DVT) segment is the higher prevalence of pulmonary embolism (PE) and the increasing occurrence of existing cardiovascular conditions, blood disorders, and obesity. The heart attacks segment is also anticipated to grow because anticoagulants are indispensable for the prevention of more myocardial infarctions for individuals who have already suffered one heart attack. For individuals with atrial fibrillation and a higher risk of stroke, anticoagulant therapy is recommended.

By Route of Administration Outlook

“Oral to hold a Leading Position in the Blood Thinners Market in Terms of Revenue Generation in the Forecast Period.”

On the basis of route of administration, the global market can be segmented into oral and injectable. Oral anticoagulants are expected to generate the highest market revenue during the forecast period. Oral anticoagulants are one of the most common and traditional modes of administration of anticoagulant therapy, and they are anticipated to expand during the forecast period. Oral anticoagulants segment is further anticipated to grow because of prominent product launches in this segment. Due to technological advances in anticoagulants and their contribution to a substantial reduction in risk, this segment is further anticipated to undergo growth in the forecast period.

Despite lower revenues in the forecast period and a lower CAGR, the injectable segment is anticipated to see some significant presence in the forecast period due to warfarin, which is also present in injectable form. This anticoagulant was one of the earliest on the market and still plays a significant role in the reduction of blood clots, but the high presence of generics remains a limiting factor.

By Distribution Channel Outlook

“Hospital Pharmacies Segment is expected to hold the Highest Share among Distribution Channels.”

The global market can be segmented by distribution channel into hospital pharmacies, retail pharmacies, online pharmacies, and others. The hospital pharmacies segment is anticipated to have a dominant share because the usage of these anticoagulants is riskier and is often prescribed after a thorough diagnosis, which is often conducted at these locations. By distribution channel, the hospital pharmacies segment is expected to hold a 46.1% share in 2025.

According to anticoagulants market trends, the retail pharmacies segment is anticipated to hold the second largest share because these institutions are able to provide more efficient facilities for re-filling prescriptions. The online pharmacies segment is anticipated to experience the highest CAGR for revenue due to the increasing usage of online pharmacy facilities, which are gaining popularity due to their ease and convenience.

REGIONAL ANALYSIS

To get more information on the regional analysis of this market, Download Free sample

North America generated a revenue of USD 18.90 billion in 2024 and is anticipated to emerge dominant in the global market during the forecast period. The high prevalence of cardiovascular diseases which require treatment through anticoagulants, coupled with the new product launches across the region, will drive the market growth in the region. Besides this, the increasing research and development initiatives, coupled with increasing awareness and high presence of risk factors such as obesity and diabetes in the general population, is expected to drive the market in North America during the forecast period.

Asia Pacific is expected to witness the highest growth in the market value. Due to the increasing disposable incomes across the region, there is greater awareness of cardiovascular diseases. The increasing prevalence of cardiovascular diseases in the key countries in the region, adoption of advanced anticoagulants, and the increasing status of cardiovascular diseases as the leading cause of mortality are also anticipated to drive the blood thinners market growth across the region. The anticoagulants market in Japan is expected to reach USD 3.21 billion by 2025. China is projected to witness a strong CAGR of 13.40% during the forecast period.

On the other hand, Europe is projected to witness significant growth in the market because cardiovascular disease causes more than half of all deaths across the region, which is resulting in the higher adoption of blood thinning medications. The high growth countries, including the U.K., France, and Germany would contribute to the growth of the European market. Europe is anticipated to grow at a CAGR of 7.6% during the forecast period.

The Latin America market for anticoagulant drugs is anticipated to undergo robust growth due to the increasing prevalence of cardiovascular diseases such as heart attacks. The Middle East and Africa is expected to witness steady growth in the future due to the rising prevalence of cardiovascular diseases and greater adoption of advanced anticoagulant drugs.

INDUSTRY KEY PLAYERS

“Market Players like Bristol-Myers Squibb Company, Pfizer Inc., and Janssen Pharmaceuticals, Inc. to Strengthen the Market Position”

Some key companies dominate the global market due to their strong product portfolio, key strategic decisions, and dominance of market share. These include a group of 2-3 key companies with wider geographic presence and continued R&D resulting in strong regulatory approvals. The global market is mature, has a heavy presence of generics especially for earlier launched anticoagulants, and is difficult in terms of entry of new competitors without breakthrough drug formulations

LIST OF TOP ANTICOAGULANTS COMPANIES:

• Bristol-Myers Squibb Company
• Pfizer Inc.
• Bayer AG
• Janssen Pharmaceuticals, Inc.
• Eisai Co., Ltd.
• Other Prominent Players

KEY INDUSTRY DEVELOPMENTS:

• February 2021 - The Stony Brook study discovered that using an anticoagulation therapy based on blood serum D-dimer levels reduced mortality in critically ill Covid-19 Patients.
• September 2020 - Mylan N.V. announced that the company had signed an agreement to acquire Aspen Pharmacare Holdings Limited's thrombosis business in Europe. This acquisition will help the company be positioned as the second-largest supplier of injectable anticoagulant products to patients in Europe.
• September 2020 – Mylan announced that the company would pay Aspen $756 million to boost the Euro portfolio of Aspen Pharmacare's sterile injectable anticoagulants. This deal will help the company to strengthen its reach in hospitals and enhance the future growth of our biosimilars franchise in Europe

REPORT COVERAGE

The increasing awareness of cardiovascular diseases, lifestyle risk factors such as diabetes and obesity, and new product launches based on advanced technologies is expected to increase the global anticoagulants market growth. 

Along with this, the anticoagulants market report provides an extensive analysis of the global market dynamics and competitive landscape and scenario. Various key insights presented in the report are the prevalence of major cardiovascular diseases by key countries, overview of novel oral anticoagulants (NOACs), pipeline analysis, key industry developments such as mergers & acquisitions, new product launches, the regulatory scenario in key countries, reimbursement scenario by key countries, and advances in R&D for novel therapeutics. Along with this other key insight includes key strategies adopted by market leaders, competitive landscape, and company profiles.

To gain extensive insights into the market, Download for Customization

Report Scope & Segmentation